Ask an Expert
BENGALURU | May 23, 2026: In a significant operational upgrade, Danish pharmaceutical Novo Nordisk is aggressively deploying artificial intelligence across its Global Business Services (GBS) center in Bengaluru, significantly expanding the role of the GBS as part of a broader enterprise-wide push toward AI-enabled drug commercialization, regulatory modernization, and intelligent healthcare operations. The strategic objective is massive: utilizing the local hub to slash post-trial drug launch timelines by up to two-thirds.
The move reflects a larger transformation underway across the global pharmaceutical industry, where AI, automation, scientific computing, and advanced analytics are increasingly being embedded into core operational workflows spanning regulatory affairs, pharmacovigilance, clinical analytics, and commercial launch preparation.
Headquartered in Denmark, Novo Nordisk is a global pharmaceutical and focuses primarily on diabetes and obesity care (widely known for therapeutics like Ozempic and Wegovy) and rare blood and endocrine diseases. As the company scales its pipeline to meet unprecedented global demand, it is actively restructuring its enterprise architecture to eliminate regulatory bottlenecks-positioning its Indian capability center at the very heart of this transformation. Novo Nordisk reported revenues exceeding US$40 billion in 2025, while the global obesity therapeutics market itself is projected to surpass US$100 billion over the next decade as healthcare systems increasingly prioritize metabolic disease management and chronic care innovation.
Against this backdrop, the company is scaling its digital, AI, and enterprise capability infrastructure globally, with Bengaluru emerging as a strategically important node within that transformation.
Historically, from ‘last patient, last visit’ to first filing might have been a year and a half. What we’re able to do now by implementing AI is bring that time down by month… A good proportion of the work for any market (launch) would be done out of the India centre. There’s probably not a medicine launched anywhere in the world that hasn’t had a thumbprint of Bangalore on it.
AI Targets One of Pharma’s Biggest Operational Bottlenecks
One of the most significant operational challenges facing global pharmaceutical companies occurs after clinical trials conclude. Preparing regulatory submissions, synthesizing clinical evidence, compiling safety documentation, managing data validation, and coordinating compliance-heavy workflows across global markets can often take several months to more than a year depending on the complexity of the therapy and jurisdictional requirements.
Industry estimates suggest regulatory and compliance-related activities can account for nearly 15-25% of overall drug development and commercialization costs globally. Novo Nordisk is now leveraging AI and advanced analytics capabilities within its Bengaluru operations to help streamline portions of this post-trial regulatory lifecycle. Rather than replacing scientific or regulatory expertise, the company’s AI initiatives appear focused on reducing high-friction operational workflows through automation-assisted documentation, intelligent data synthesis, predictive analytics, and faster processing of large-scale clinical information.
Key areas of focus reportedly include:
- AI-assisted regulatory drafting and medical documentation support
- Clinical data analytics and safety signal processing
- Commercial analytics for marketed and pipeline therapies
- Intelligent workflow automation for regulatory operations
- Enterprise data modernization and digital reporting systems
Industry observers note that these capabilities are increasingly becoming critical competitive differentiators within the pharmaceutical sector as companies race to accelerate commercialization timelines, improve operational efficiency, and manage rapidly expanding therapy pipelines.
Bengaluru’s Role Is Expanding Beyond Traditional Support Functions
Novo Nordisk’s Bengaluru center is also reflective of a broader evolution in how life sciences GCCs are being structured globally. Historically, pharmaceutical capability centers in India largely focused on transactional operations, IT support, finance, or limited analytics functions. That operating model is changing rapidly.
Increasingly, India-based centers are being trusted with highly specialized, science-linked enterprise functions including pharmacovigilance, medical writing, clinical analytics, bioinformatics, regulatory operations, AI-driven data intelligence, and digital health platforms.
Industry sources indicate Novo Nordisk’s Bengaluru operations now support a substantial share of the company’s global pharmacovigilance and regulatory support activities – functions that require highly specialized talent spanning medicine, pharmacy, data science, analytics, and healthcare technology.
The center has also reportedly played an important role in supporting global launch preparation activities for emerging therapies, including operational support spanning clinical data management, analytics, and scientific documentation workflows. This reflects a larger shift within the life sciences sector where global pharmaceutical companies are increasingly repositioning India operations from cost-arbitrage support models into strategically embedded enterprise capability hubs.
AI Is Reshaping the Global Pharma Operating Model
The strategic significance of Novo Nordisk’s Bengaluru operations extends beyond one company’s expansion strategy. Across the pharmaceutical industry, AI adoption is accelerating rapidly across drug discovery, regulatory intelligence, pharmacovigilance, trial optimization, manufacturing analytics, patient monitoring, and commercialization operations.
The global AI-in-pharma market is projected to exceed US$15-20 billion by 2030 as pharmaceutical enterprises invest heavily in intelligent automation, predictive analytics, scientific computing, and digital health ecosystems. However, industry experts emphasize that the most immediate productivity gains from AI are often occurring not inside laboratories, but across operational and regulatory workflows that traditionally involve large-scale manual processing, documentation complexity, and fragmented data systems.
This includes:
- regulatory documentation preparation,
- adverse-event monitoring,
- compliance reporting,
- clinical data interpretation,
- scientific literature analysis,
- and enterprise knowledge management.
Novo Nordisk’s Bengaluru strategy appears closely aligned with this broader industry direction.
